Myriad Genetics Reports Results for Quarter Ended June 30, 2026

What Happened

• Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2026 in an earnings release dated July 30, 2026. The earnings release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference. The filing includes a cautionary note regarding forward-looking statements.

Key Details

• Filing date: July 30, 2026 (Form 8-K Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months ended June 30, 2026.
• Exhibit: Earnings release dated July 30, 2026 is attached as Exhibit 99.1.
• The filing references customary forward-looking statements and related cautions; interactive XBRL data is included (Exhibit 104).

Why It Matters

• This filing provides Myriad’s most recent quarterly performance figures and management commentary (contained in Exhibit 99.1), which are material for assessing near-term revenue, profitability and trends. Retail investors should review the attached earnings release for specific metrics (revenue, net income or loss, EPS, guidance if provided) and any management discussion of business outlook or risks before making investment decisions.